Cytokinetics, Incorporated (CYTK)

Market Cap	8.44B +28.9%
Revenue (ttm)	67.67M -21.1%
Net Income	-894.00M
EPS	-7.18
Shares Out	139.02M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	783,172
Open	61.45
Previous Close	61.23
Day's Range	60.48 - 61.89
52-Week Range	57.83 - 88.31
Beta	0.41
Analysts	Strong Buy
Price Target	109.20 (+79.81%)
Earnings Date	Nov 4, 2026

About CYTK

Cytokinetics, Incorporated, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel muscle activators and muscle inhibitors as potential treatments for debilitating diseases in the United States. The company markets MYQORZO, a novel, oral, and small molecule cardiac myosin inhibitor for the treatment of symptomatic oHCM. It also develops Aficamten, a novel, oral, and small molecule cardiac myosin inhibitor for the treatment of HCM; and omecamtiv mecarbil, a potential treatment across the continuum of care in h...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Apr 29, 2004
• Employees: 673
• Stock Exchange: Nasdaq
• Ticker Symbol: CYTK
• Website: https://www.cytokinetics.com

Financial Performance

In 2025, Cytokinetics's revenue was $88.04 million, an increase of 376.56% compared to the previous year's $18.47 million. Losses were -$784.96 million, 33.2% more than in 2024.

Analyst Summary

According to 23 analysts, the average rating for CYTK stock is "Strong Buy." The 12-month stock price target is $109.2, which is an increase of 79.81% from the latest price.

Price Target

$109.2

(79.81% upside)

Analyst Consensus: Strong Buy

Data Sources: S&P Global Market Intelligence, CBOE, and more

Fundamental and historical data is provided by S&P Global Market Intelligence. Real-time stock price data is provided by CBOE and 15-minute delayed consolidated tape pricing data is provided by Nasdaq UTP.

Last checked:

Oct 27, 2026

Data Sources Report a data error